|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Randomized, double-blind ,placebo-controlle, phase BI cross-over study evaluatingthe oral neurokinin-1 antagonist aprepitant in combination witha5HT3 receptor antagonist and dexamethasone in patients with ger-mcell tumors receiving 5-day cisplatin combination chemotherapyregimens : a hoosier oncology group study 显示文摘 | Albany C Brames MJ Fausel C | 2012 | J Clin Oncol2012，30，32： | 1 |
| 2 | Out-of-hospital airway management by paramedics and emergency physicians using laryngeal tubes显示文摘 | Schaik R Byhahn C Fausel F | 2010 | Re suscitation2010，81，3： | 1 |
| 3 | Targeted chronic myeloid leukemia therapy: seeking a cure 显示文摘 | Fausel C | 2007 | Am J Health Syst Pharm2007，64，2415： | 1 |
| 4 | Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide,thalidomide,and prednisone for patients with relapsed or refractory multiple myeloma:A hoosier oncology group trial,HEM01-21显示文摘 | Suvannasankha A Fausel C Juliar BE | 2007 | Oncologist2007，12，1： | 1 |
| 5 | Randomized, double-blind,placebo-controlled, phase III cross-over study evaluating the oralneurokinin-1antagonist aprepitant in combination with a 5HT3 receptorantagonist and dexamethasone in patients with germ cell tumors receiving5-day cisplatin combination chemotherapy regimens: a hosier oncologygroup study显示文摘 | Albany C1 Brames MJ Fausel C | 2012 | J ClinOncol2012，30，32： | 1 |
| 6 | Randomized, doubleblind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-l antagonist aprepitant in combination with a 5 HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study显示文摘 | Albany C Brames MJ Fausel C | 2012 | J Clin Oncol2012，30，32： | 1 |
| 7 | Final report of toxicity and efficacy of a phase Ⅱ study of oral cydophosphamide,thalidomide,and prednisone for patients with relapsed or refractory multiple myeloma:A Hoosier Oncology Group Trial,HEM0121显示文摘 | Suvannasankha A Fausel C Juliar BE | 2007 | Oncologist2007，12，1： | 1 |
| 8 | Targeted chronic myeloid leukemia therapy:Seekinga cure显示文摘 | FAUSEL C | 2007 | Am J Health Syst Pharm2007，64，2415： | 1 |
| 9 | Final report of toxicity and efficacy of a phase Ⅱ study of oral cyclophosphamide,thalidomide,and prednisone for patients with relapsed or refractory multiple myeloma:A hoosier oncology group trial,HEM01-21显示文摘 | Suvannasankba A Fausel C Juliar BE | 2007 | The Oncologist2007，12，1： | 1 |
| 10 | Final report of toxicity and efficacy of a phase Ⅱ study of oral cyclophosphamide,thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A HoosierOncology Group Trial, HEM01-21 显示文摘 | Suvannasankha A Fausel C Juliar B E | 2007 | Oncologist2007，12，1： | 1 |
| 11 | Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5-HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study显示文摘 | Albany C Brames MJ Fausel C | 2012 | J Clin Oncol2012，30，32： | 1 |
| 12 | Final report of toxicity and efficacy of a phase Ⅱ study of oral cyclophosphamide,thalidomide,and prednisone for patients with relapsed or refractnry multiple myeloma:a Hoosier oncology Group Trial,HEMO1-21 显示文摘 | Suvannasankha A Fausel C Juliar BE | 2007 | Oncologist2007，12，1： | 1 |
| 13 | Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide,thalidomide,and prednisone for patients with relapsed or refractory multiple myeloma:a hoosier oncology group trial,HEM01-21显示文摘 | Suvannasankha A Fausel C Juliar BE | 2007 | Oncologist2007，12，1： | 1 |
| 14 | Randomized, dou- ble-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexa- methasone in patients with germ cell tumors receiving 5- day cisplatin combination chemotherapy regimens: a hoosier oncology group study显示文摘 | Albany C Brames M J Fausel C | 2012 | J Clin Oncol2012，30，32： | 1 |
| 15 | Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a hoosier oncology group trial, HEM01-21 显示文摘 | Suvannasankha A Fausel C Juliar BE | 2007 | Oncologist2007，12，1： | 1 |
| 16 | Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for pa- tients with relapsed or refractory mtdtiple myeloma: a Hoosier Ontology Group Trial, HEM01-21 显示文摘 | Suvannasankha A Fausel C Juliar B E | 2007 | Oncolo- gist2007，12，1： | 1 |
| 17 | Final report of toxicity and efficacy of a phase Ⅱ study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21 显示文摘 | Suvannasankha A Fausel C Juliar B E | 2007 | Oncologist2007，12，1： | 1 |
| 18 | Final report of toxicity and efficacy of a phase Ⅱ study of oral cyclophosphamide,thalidomide,and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HE M01-21 显示文摘 | Suvannasankha A Fausel C Juliar B E | 2007 | Oncologist2007，12，1： | 1 |
| 19 | Final report of toxicity and efficacy of a phase Ⅱ study of oral cyclophosphamide,thalidomide,and prednisone for patients with relapsed or refractory multiple myeloma:A Hoosier Oncology Group Trial,HEM01-21显示文摘 | Fausel C Juliar BE | 2007 | Oncologist2007，12，1： | 1 |
| 20 | Targeted chronic myeloid leukemia therapy: Seeking a cure显示文摘 | Fausel C | 2007 | Am J Health Syst Pharm2007，64，2415： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员